Rene H Medema

Scientific Director

Princess Maxima Center
Country flagNetherlands

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (42)

Homologous recombination (HR) is a DNA repair process that requires a homologous sequence for the repair of DNA double-stranded breaks. The search for homology is the rate limiting step for HR, but the dynamics of homology search in vivo are currently poorly understood. This is largely due to a lack of tools to visualize homology search in action in living human cells. Here, we show that RAD51 and MND1, two proteins operating in homology search, become visible in long filamentous structures several hours after double-stranded break formation. Using GFP-MND1 we can visualize these filaments in living human cells and find that they are highly dynamic, explore the nuclear space, and can resolve over time. We show that the resolution of these filaments depends on RAD54L, known for its role in RAD51-driven homology search and strand-invasion. In addition, we find that loss of cohesin also inhibits the resolution of these filaments, in accordance with a role for cohesin in HR. Thus, our data suggest that these filaments are visible intermediates of an active DNA repair process, and that MND1-GFP can be used as a tool to study the dynamics of homology search in living human cells.

Year:

2025

High fidelity of replication is important to preserve genomic integrity and ensure healthy progeny. Perturbations of replication, also known as replication stress, is frequently observed in cancer cells and is considered a cancer cell-specific trait. Although replication stress drives genomic instability and tumor progression, it also generates a targetable cancer-specific vulnerability. In order to identify potential therapeutic targets in cancer cells that experience replication stress, we performed a genome wide genetic screen in human HAP1 cells challenged with low doses of replication stress-inducing drugs. We identified a large set of genes that specifically hamper cell survival in the context of replication stress. In addition to well-known players in the replication stress response and DNA repair, such as RNASEH1, BRIP1, and MDC1, we identified several genes with no prior described role in DNA replication, damage tolerance or repair. We validated that the loss of GIGYF2, HNRNPA2B1, and SUMO2 renders cells more vulnerable to replication stress. For GIGYF2 and SUMO2, we could implicate a role in homologous recombination. Taken together, our replication stress screen identified several known as well as some novel factors that protect against the toxic implications of replication stress. These factors could entail potential therapeutic targets for cancer cells experiencing replication stress.

Year:

2025

Lamina-associated domains (LADs) are megabase-sized genomic regions anchored to the nuclear lamina (NL). Factors controlling the interactions of the genome with the NL have largely remained elusive. Here, we identified DNA topoisomerase 2 beta (TOP2B) as a regulator of these interactions. TOP2B binds predominantly to inter-LAD (iLAD) chromatin and its depletion results in a partial loss of genomic partitioning between LADs and iLADs, suggesting that its activity might protect specific iLADs from interacting with the NL. TOP2B depletion affects LAD interactions with lamin B receptor (LBR) more than with lamins. LBR depletion phenocopies the effects of TOP2B depletion, despite the different positioning of the two proteins in the genome. This suggests a complementary mechanism for organising the genome at the NL. Indeed, co-depletion of TOP2B and LBR causes partial LAD/iLAD inversion, reflecting changes typical of oncogene-induced senescence. We propose that a coordinated axis controlled by TOP2B in iLADs and LBR in LADs maintains the partitioning of the genome between the NL and the nuclear interior. Highlights LADs and iLADs differ in supercoiling state TOP2B controls genome partitioning between nuclear lamina and nuclear interior TOP2B depletion preferentially affects genome interactions with LBR Similar impact of TOP2B depletion and LBR depletion on genome-NL interactions Co-depletion of TOP2B and LBR recapitulates LAD reshaping typical of oncogene-induced senescence.

Year:

2024

Aneuploidy, while detrimental to untransformed cells, is notably prevalent in cancer. Aneuploidy is found as an early event during tumorigenesis which indicates that cancer cells have the ability to surmount the initial stress responses associated with aneuploidy, enabling rapid proliferation despite aberrant karyotypes. To generate more insight into key cellular processes and requirements underlying adaptation to aneuploidy, we generated a panel of aneuploid clones in p53-deficient RPE-1 cells and studied their behavior over time. As expected, de novo-generated aneuploid clones initially display reduced fitness, enhanced levels of chromosomal instability (CIN), and an upregulated inflammatory response. Intriguingly, after prolonged culturing, aneuploid clones exhibit increased proliferation rates while maintaining aberrant karyotypes, indicative of an adaptive response to the aneuploid state. Interestingly, all adapted clones display reduced CIN and reduced inflammatory signaling, suggesting that these are common aspects of adaptation to aneuploidy. Collectively, our data suggests that CIN and concomitant inflammation are key processes that require correction to allow for fast proliferation in vitro. Finally, we provide evidence that amplification of oncogenic KRAS can promote adaptation.

Year:

2024

Figure S9: Single-cell RNAseq identify transcriptional signatures downregulated in CRC cells after acquired resistance to the combination of LB-100 and adavosertib UMAP representations of HT-29 (A) and SW-480 (B) cells colored by the activity scores for the indicated pathways. UMAPs colored by sample of origin from both cell lines are present of the left for reference. The boxen plots show the pathway activity scores for parental (red) and resistant (blue) cells.

Year:

2024

Figure S3: High N-Myc levels sensitize neuroblastoma cells to LB-100, and PP2A knockdown sensitizes CRC cells to WEE1 inhibition (A) Western blots comparing N-Myc levels in isogenic neuroblastoma models. GAPDH was used as a loading control. (B) long-term viability assays compares the toxicity of LB-100 across these neuroblastoma models. LB-100 was refreshed every 2-3 days, and the cells were grown for 10 days before fixing, staining, and imaging. (C) Western blots show the knockdown of PPP2R1A in HT-29 and SW-480 cells. GAPDH was used as a loading control. (D) Dose-response assays show the effect of Adavosertib after PPP2R1A knockdown compared to a control shRNA in HT-29 and SW-480 cells. Cell viability was estimated by resazurin fluorescence after 5 days in the presence of the drug or DMSO control. The normalized values are plotted. (E) The heat map shows all “Hallmarks” and “KEGG” molecular signatures significantly enriched by LB-100 (4 µM), calyculin A (5 nM), or okadaic acid (10 nM) in HT-29 and SW-480 cells after 8 hours. Asterisks indicate significance level (* p-value

Year:

2024

Figure S10: Acquired resistance to the combination of LB-100 and Adavosertib suppress anchorage-independent and tumor growth in CRC models (A) Endpoint proliferation of HT-29 and SW-480 parental and resistant cells growing attached or in anchorage-independent conditions. Cells were plated in the same density on regular or cell-repellent culture plates in the absence of drugs and grown for 5-6 days. Proliferation was addressed by CellTiter-Glo 3D® and is expressed as fold change over T0. (B) Growth curves of the individual tumors from SW-480 parental and resistant cells measured 3 times per week. The dashed line indicates the 1500 mm3 ethical sacrifice.

Year:

2024

Supplementary table 6: Stress-focused drug screens AUC differences in SW-480 cells Area Under the Curve (AUC) from each compound of the stress-focused drug screen in the presence or absence of LB-100. Compounds are ranked by the difference in the AUC between LB-100-treated and untreated samples.

Year:

2024

Supplementary table 6: Stress-focused drug screens AUC differences in SW-480 cells Area Under the Curve (AUC) from each compound of the stress-focused drug screen in the presence or absence of LB-100. Compounds are ranked by the difference in the AUC between LB-100-treated and untreated samples.

Year:

2024

Supplementary table 3: Full list of genes whose knockout attenuated LB-100 toxicity in SW-480 cells in the CRISPR-KO screen FDR smaller or equal to 0.25 and log2 fold change greater or equal to 1 in treated/untreated comparison were criteria for hit selection.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (17)

Kees Jalink

Professor

University of Amsterdam

NETHERLANDS
View details

Stefano Giustino Manzo

Assistant Professor

University of Milano-Bicocca

ITALY
View details

Roderick Beijersbergen

Professor and head division

The Netherlands Cancer Institute

NETHERLANDS
View details

Femke Feringa

University of Amsterdam

NETHERLANDS
View details

Bas van Steensel

Antoni van Leeuwenhoek Nederlands Kanker Instituut

NETHERLANDS
View details

Sara Mainardi

The Netherlands Cancer Institute

NETHERLANDS
View details

João M Fernandes Neto

Junior Researcher

i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto

PORTUGAL
View details

Stefan Prekovic

Group leader

Universitair Medisch Centrum Utrecht

NETHERLANDS
View details

Nick Gilbert

Principal Investigator

University of Edinburgh

UNITED KINGDOM
View details

Jan van Weering

University of Amsterdam

NETHERLANDS
View details

Elzo de Wit

The Netherlands Cancer Institute

NETHERLANDS
View details

Rene Bernards

Advisory Professor

Shanghai Jiao Tong University

CHINA
View details

Anoek Friskes

The Netherlands Cancer Institute

NETHERLANDS
View details

Hugo A Armelin

Professor Titular de Bioquímica

University of Sao Paulo

BRAZIL
View details

August Vidal

Professor Associat Mèdic

University of Barcelona

SPAIN
View details

Emmanuelle Jeannot

Institut Curie

FRANCE
View details

Chiara Maria Cattaneo

Junior Group Leader

IRCCS Humanitas Research Hospital

ITALY
View details